News Releases November 21, 2023 Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference Read more November 10, 2023 Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference Read more November 9, 2023 Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress Read more November 6, 2023 Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update Read more October 9, 2023 Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis Read more August 30, 2023 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more August 10, 2023 Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress Read more August 3, 2023 Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023 Read more August 2, 2023 Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference Read more June 14, 2023 Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor Read more Current page 1 Page 2 Page 3 Page 4 Page 5 Next page › Last page » Displaying 1 - 10 of 45
